Charles River Laboratories International Inc
CRL143.323USD
-7.707-5.10%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
7.04BCap. mercado
683.63P/E TTM
Más Datos de Charles River Laboratories International Inc Compañía
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Información de la empresa
Símbolo de cotizaciónCRL
Nombre de la empresaCharles River Laboratories International Inc
Fecha de salida a bolsaJun 23, 2000
Fundada en1994
Director ejecutivoMr James C. Foster
Número de empleados18600
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 23
Dirección251 Ballardvale St
CiudadWILMINGTON
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal01887
Teléfono17812226000
Sitio Webhttps://www.criver.com/
Símbolo de cotizaciónCRL
Fecha de salida a bolsaJun 23, 2000
Fundada en1994
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr James C. Foster
Mr James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
13.68K
-2.74%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
3.96K
+31.35%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
2.59K
+155.42%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
2.41K
+64.49%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
946.00
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr James C. Foster
Mr James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
13.68K
-2.74%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Por negocioUSD
Nombre
Ganancia
Proporción
DSA
2.45B
60.53%
RMS
829.38M
20.48%
Manufacturing
769.33M
19.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
2.24B
55.31%
Europe
1.08B
26.62%
Canada
482.09M
11.90%
Asia Pacific (Region)
196.95M
4.86%
Other
52.82M
1.30%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
DSA
2.45B
60.53%
RMS
829.38M
20.48%
Manufacturing
769.33M
19.00%
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
12.41%
Wellington Management Company, LLP
8.72%
BlackRock Institutional Trust Company, N.A.
5.92%
UBS Financial Services, Inc.
4.86%
Kayne Anderson Rudnick Investment Management, LLC
3.97%
Other
64.11%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
12.41%
Wellington Management Company, LLP
8.72%
BlackRock Institutional Trust Company, N.A.
5.92%
UBS Financial Services, Inc.
4.86%
Kayne Anderson Rudnick Investment Management, LLC
3.97%
Other
64.11%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
51.53%
Investment Advisor
39.65%
Hedge Fund
7.75%
Research Firm
7.70%
Pension Fund
1.84%
Bank and Trust
1.53%
Sovereign Wealth Fund
1.10%
Individual Investor
1.05%
Insurance Company
0.08%
Participación institucional
Actualizado: lun., 20 de ene
Actualizado: lun., 20 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
1407
54.59M
111.11%
-3.65M
2024Q4
1423
54.85M
107.26%
-4.35M
2024Q3
1392
53.78M
105.14%
-5.12M
2024Q2
1399
54.00M
104.84%
-4.00M
2024Q1
1393
53.76M
104.37%
-4.04M
2023Q4
1424
53.56M
104.42%
-4.24M
2023Q3
1446
53.56M
104.42%
-3.98M
2023Q2
1427
52.88M
103.32%
-3.95M
2023Q1
1431
52.72M
103.01%
-2.79M
2022Q4
1416
51.28M
100.65%
-3.46M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
6.13M
12.49%
+58.13K
+0.96%
Dec 31, 2024
Wellington Management Company, LLP
4.08M
8.3%
+335.66K
+8.97%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
2.95M
6.01%
-51.78K
-1.72%
Dec 31, 2024
Kayne Anderson Rudnick Investment Management, LLC
1.81M
3.68%
-134.28K
-6.92%
Dec 31, 2024
State Street Global Advisors (US)
2.18M
4.44%
+51.15K
+2.40%
Dec 31, 2024
Allspring Global Investments, LLC
1.81M
3.68%
+47.22K
+2.68%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.23M
2.51%
+14.79K
+1.21%
Dec 31, 2024
Impactive Capital LP
1.20M
2.45%
+825.95K
+219.44%
Dec 31, 2024
Ariel Investments, LLC
1.07M
2.17%
+169.64K
+18.90%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
First Trust NASDAQ Pharmaceuticals ETF
1.63%
ROBO Global Healthcare Technology & Innovation ETF
1.41%
VanEck Biotech ETF
1.41%
Schwab Ariel ESG ETF
1.35%
Invesco S&P 500 Equal Weight Health Care ETF
1.34%
Franklin Genomic Advancements ETF
1.25%
Invesco S&P 500 High Beta ETF
0.9%
Principal Quality ETF
0.78%
iShares Health Innovation Active ETF
0.7%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.68%
Ver más
First Trust NASDAQ Pharmaceuticals ETF
Proporción1.63%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.41%
VanEck Biotech ETF
Proporción1.41%
Schwab Ariel ESG ETF
Proporción1.35%
Invesco S&P 500 Equal Weight Health Care ETF
Proporción1.34%
Franklin Genomic Advancements ETF
Proporción1.25%
Invesco S&P 500 High Beta ETF
Proporción0.9%
Principal Quality ETF
Proporción0.78%
iShares Health Innovation Active ETF
Proporción0.7%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
Proporción0.68%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
